(Q36589344)

15 August 2017

1 reference

title

Who should receive a statin these days? Lessons from recent clinical trials (English)

1 reference

15 August 2017

Shepherd J

1

1 reference

PubMed ID

16961668

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

Journal of Internal Medicine

15 August 2017

1 reference

15 August 2017

260

1 reference

15 August 2017

305-319

1 reference

15 August 2017

4

1 reference

Therapeutic effects of ML-236B in primary hypercholesterolemia

15 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. Multinational MONItoring of Trends and Determinants in CArdiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

The Myocardial Ischemia Reduction with Acute Cholesterol Lowering (MIRACL) trial: a new frontier for statins?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

The issue of statin safety: where do we stand?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project—A combined analysis of three large-scale randomized trials: Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID), Cholesterol and Re

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by i

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2006.01700.X

10.1111/J.1365-2796.2006.01700.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

16961668